CN112384497A - 具有选择性nox抑制活性的新型磺酰胺衍生物 - Google Patents
具有选择性nox抑制活性的新型磺酰胺衍生物 Download PDFInfo
- Publication number
- CN112384497A CN112384497A CN201980031256.XA CN201980031256A CN112384497A CN 112384497 A CN112384497 A CN 112384497A CN 201980031256 A CN201980031256 A CN 201980031256A CN 112384497 A CN112384497 A CN 112384497A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- sulfonamide
- disorders
- benzene
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
- C07D213/34—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18171556.6 | 2018-05-09 | ||
EP18171556 | 2018-05-09 | ||
PCT/EP2019/061950 WO2019215291A1 (en) | 2018-05-09 | 2019-05-09 | Novel sulfonamide derivatives having selective nox inhibiting activity |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112384497A true CN112384497A (zh) | 2021-02-19 |
Family
ID=62148213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980031256.XA Pending CN112384497A (zh) | 2018-05-09 | 2019-05-09 | 具有选择性nox抑制活性的新型磺酰胺衍生物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210171456A1 (ko) |
EP (1) | EP3790858A1 (ko) |
JP (1) | JP7455762B2 (ko) |
KR (1) | KR20210008493A (ko) |
CN (1) | CN112384497A (ko) |
AU (1) | AU2019267105A1 (ko) |
BR (1) | BR112020022406A2 (ko) |
CA (1) | CA3099093A1 (ko) |
MX (1) | MX2020011769A (ko) |
WO (1) | WO2019215291A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202413355A (zh) | 2022-05-09 | 2024-04-01 | 瑞士商卡利迪塔斯療法瑞士股份有限公司 | 新醫藥用途 |
KR20240002032A (ko) | 2022-06-28 | 2024-01-04 | 동국대학교 산학협력단 | Nadph 산화효소 2 저해제로서의 신규 화합물 및 이를 포함하는 약학조성물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005015040A1 (de) * | 2005-03-31 | 2006-10-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
WO2007076055A2 (en) | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
BRPI0714554A2 (pt) | 2006-07-25 | 2013-05-07 | Sanofi Aventis | 2-fenil-indàis como antagonistas do receptor de prostaglandina d2 |
JP6768662B2 (ja) | 2014-12-16 | 2020-10-14 | グルソックス・バイオテック・アーベー | Nadphオキシダーゼに関連する状態の処置に使用するための化合物 |
WO2017209272A1 (ja) | 2016-06-03 | 2017-12-07 | 国立大学法人東京大学 | がん転移阻害剤 |
-
2019
- 2019-05-09 CA CA3099093A patent/CA3099093A1/en active Pending
- 2019-05-09 WO PCT/EP2019/061950 patent/WO2019215291A1/en active Application Filing
- 2019-05-09 EP EP19723103.8A patent/EP3790858A1/en active Pending
- 2019-05-09 US US17/052,224 patent/US20210171456A1/en active Pending
- 2019-05-09 MX MX2020011769A patent/MX2020011769A/es unknown
- 2019-05-09 KR KR1020207034878A patent/KR20210008493A/ko not_active Application Discontinuation
- 2019-05-09 AU AU2019267105A patent/AU2019267105A1/en active Pending
- 2019-05-09 JP JP2020562578A patent/JP7455762B2/ja active Active
- 2019-05-09 BR BR112020022406-5A patent/BR112020022406A2/pt active Search and Examination
- 2019-05-09 CN CN201980031256.XA patent/CN112384497A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3099093A1 (en) | 2019-11-14 |
US20210171456A1 (en) | 2021-06-10 |
EP3790858A1 (en) | 2021-03-17 |
MX2020011769A (es) | 2021-01-29 |
BR112020022406A2 (pt) | 2021-04-13 |
JP7455762B2 (ja) | 2024-03-26 |
KR20210008493A (ko) | 2021-01-22 |
WO2019215291A1 (en) | 2019-11-14 |
JP2021523135A (ja) | 2021-09-02 |
AU2019267105A1 (en) | 2021-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009500357A (ja) | 肥満、インスリン抵抗性障害およびミトコンドリア関連障害を処置または予防するための方法および関連する組成物 | |
JP7455762B2 (ja) | 選択的なNox阻害活性を有する新規のスルホンアミド誘導体 | |
WO2018175537A1 (en) | Selective inhibition of gluconeogenic activity | |
KR20200015888A (ko) | Nav1.7 및 Nav1.8 차단제로 쓰이는 아미드 유도체 | |
WO2020079569A1 (en) | Compositions and methods for suppressing and/or treating metabolic diseases and/or a clinical condition thereof | |
CA2989271C (en) | Thromboxane receptor antagonists | |
EP2914597B1 (en) | Pyrazolopyridine derivatives as ttx-s blockers | |
JP7478133B2 (ja) | 腎障害の処置で使用するための化合物 | |
US9687490B2 (en) | Triazine derivatives for the treatment of conditions associated with nicotinamide adenine dinucleotide phosphate oxidase | |
RU2809030C2 (ru) | Новые производные сульфонамида, обладающие селективной nox-ингибирующей активностью | |
JP6768662B2 (ja) | Nadphオキシダーゼに関連する状態の処置に使用するための化合物 | |
WO2022090746A1 (en) | Nmt inhibitors for treating senescence-associated diseases or disorders | |
US10173988B2 (en) | N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine | |
JP2024096989A (ja) | 腎障害の処置で使用するための化合物 | |
US20150051220A1 (en) | Compounds for use in therapy | |
US20110288176A1 (en) | Ethacrynic acid-containing composition for prevention or treatment of transglutaminase-related diseases and method for prevention or treatment of transglutaminase-related diseases using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |